|
|
 |
|
Viewing report
|
|
|
|
Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine
Decision Resources, Inc., April 2009, Pages: 29
One of the fastest-growing segments of molecular diagnostics is nucleic acid testing (NAT). NAT is central to the life sciences industry, to improved healthcare, and to personalized medicine. Tools based on NAT are used to discover new biomarkers and develop in vitro diagnostics. Companies large and small are recognizing the value of NAT, and both R&D and dealmaking activity is robust. Find out who the players are and how they are vying for commercial success.
Get the Answers You Need to Shape Your Strategy
- NAT is a leading molecular diagnostics technology. What are the advantages of NAT over other molecular diagnostics technologies? Which elements of NAT will drive personalized medicine forward?
- Polymerase chain reaction (PCR) is one of the most common methods in the NAT toolbox used to discover new biomarkers and develop diagnostics tests. What other methods are commonly used for NAT? Which of these methods have the most product development activity?
- Roche Diagnostics is the clear leader in molecular diagnostics. How do Roche’s sales fi gures compare with those of smaller diagnostics players? What does the competition look like within the smaller segments? How are companies using dealmaking to advance their positions?
- Infectious disease and oncology are the two main therapy areas for use of NAT technologies. What are the growth trends and growth drivers within these therapy areas? What companies are positioned to tap the opportunities?
Scope
- Importance of NAT for advancing personalized medicine: Use of and rationale for NAT techniques and products to support the push for personalized medicine.
- Key mergers and acquisitions (M&As), collaboration, and licensing activities in NAT: Two tables featuring 92 alliances that occurred from November 2007 through December 2008.
- Leading NAT markets: Types of assays and tests within infectious disease and oncology that will continue to have a strong presence in the NAT market.
- Future trends: Insight into strategic considerations required to drive the NAT market and NAT companies forward.
Customers who bought this item also bought
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Molecular Diagnostics Markets
Personalized Medicine - Scientific and Commercial Aspects
Molecular Diagnostics - Technologies, Markets and Companies
Personalized Medicine
Cancer Personalized Medicine 2008
Innovations in Diagnostics: Next Generation Molecular and Point-of-Care Diagnostics Driving Personalized Healthcare
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways
Nucleic Acid Testing Markets in Taiwan
European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications
MicroRNA Diagnostics, Therapeutics, and Cancer Personalized Medicine 2009 Market Report
|
|
|
|
